Cyclo Therapeutics Price To Sales vs. EBITDA

CYTH Stock  USD 0.59  0.03  4.03%   
Based on Cyclo Therapeutics' profitability indicators, Cyclo Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Cyclo Therapeutics' ability to earn profits and add value for shareholders.

Cyclo Therapeutics Price To Sales Ratio

25.33

As of now, Cyclo Therapeutics' Price Sales Ratio is increasing as compared to previous years. As of now, Cyclo Therapeutics' Income Quality is increasing as compared to previous years. The Cyclo Therapeutics' current Net Income Per E B T is estimated to increase to 1.51, while Operating Income is forecasted to increase to (19 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.680.9085
Way Down
Slightly volatile
For Cyclo Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cyclo Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cyclo Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cyclo Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cyclo Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.046
Quarterly Revenue Growth
0.051
Return On Assets
(2.82)
Return On Equity
(226.64)
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cyclo Therapeutics EBITDA vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Cyclo Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyclo Therapeutics value to that of its competitors to determine the firm's financial worth.
Cyclo Therapeutics is rated second in price to sales category among its peers. It is rated below average in ebitda category among its peers . As of now, Cyclo Therapeutics' Price To Sales Ratio is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclo Therapeutics' earnings, one of the primary drivers of an investment's value.

Cyclo EBITDA vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Cyclo Therapeutics

P/S

 = 

MV Per Share

Revenue Per Share

 = 
15.85 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Cyclo Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(20.03 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Cyclo EBITDA Comparison

Cyclo Therapeutics is currently under evaluation in ebitda category among its peers.

Cyclo Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Cyclo Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cyclo Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cyclo Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cyclo Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-20.1 M-19 M
Income Before Tax-20.1 M-19.1 M
Total Other Income Expense Net-7.2 K-7.6 K
Net Loss-20.1 M-19.1 M
Income Tax Expense 4.00  3.80 
Net Loss-19.4 M-18.4 M
Net Loss-13.9 M-13.2 M
Change To Netincome328.8 K316.3 K
Net Loss(1.23)(1.29)
Income Quality 0.81  0.85 
Net Income Per E B T 1.14  1.51 

Cyclo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Cyclo Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cyclo Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cyclo Therapeutics' important profitability drivers and their relationship over time.

Use Cyclo Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Cyclo Therapeutics Pair Trading

Cyclo Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Cyclo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclo Therapeutics to buy it.
The correlation of Cyclo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Cyclo Therapeutics position

In addition to having Cyclo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Alcohol Thematic Idea Now

Alcohol
Alcohol Theme
Companies involved in production and distribution of wines and alcoholic beverages. The Alcohol theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alcohol Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:
Check out Trending Equities.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
To fully project Cyclo Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cyclo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cyclo Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Cyclo Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Cyclo Therapeutics investors may work on each financial statement separately, they are all related. The changes in Cyclo Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cyclo Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.